<DOC>
	<DOCNO>NCT00055367</DOCNO>
	<brief_summary>The purpose study determine safety tolerability natalizumab adolescent ( age 12-17 ) diagnose moderately severely active Crohn 's disease ( CD ) . It think natalizumab may stop movement certain cell , know white blood cell , bowel tissue . These cell think cause damage bowel lead symptom Crohn 's disease . Patients complete study may eligible long-term natalizumab therapy via extension protocol ELN100226-352 .</brief_summary>
	<brief_title>Safety , Tolerability Effectiveness Natalizumab Adolescents With Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Male female patient , 1217 year age , least sixmonth history Crohn 's disease currently experience moderately severely active Crohn 's disease . Females must breastfeed pregnant , must become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>